Spiracur Secures TGA Approval for SNaP Wound Care System and Announces Distribution Partnership in Australia
Spiracur and AinsCorp Team up to Bring Proven, Advanced Wound Care System to Australia and New Zealand
SUNNYVALE, Calif., Jan. 14, 2014 – Spiracur Inc., developer of the only mechanically powered advanced wound care solution with the proven efficacy of Negative Pressure Wound Therapy (NPWT), today announced that it received Australian Therapeutic Goods Administration (TGA) approval for its SNaP® Wound Care System for the treatment of chronic and acute wounds. In addition, the company announced an exclusive distribution partnership with AinsCorp Pty Ltd of Australia, whereby AinsCorp will distribute Spiracur’s SNaP System throughout Australia and New Zealand.
“I have been very impressed with the overall healing results during the initial trial of the SNaP device on one of my patients,” said Dr. Mike Klaassen, MBChB (Otago), FRACS (Plast), Parnell Surgeon, Private Practice, Auckland, New Zealand. “The small, easy-to-use system, which is clinically proven to be effective in wound healing and improving quality of life, addresses a specific need for several of my patients. As a result of my first-hand experience, I am recommending that my colleagues begin using it on their patients.”
Spiracur’s SNaP (Smart Negative Pressure®) System provides patients suffering from chronic or acute wounds with an advanced wound care solution that does not require batteries or electricity. The device weighs 62 grams and is completely silent, offering patients discreet wound care treatment.
Offering improved safety, the SNaP System may be used on patients who would benefit from wound management by the application of negative pressure. It removes infectious materials and small amounts of exudate (fluid), and stimulates tissue growth, which may promote wound healing of chronic, acute, traumatic, subacute and dehisced wounds, as well as partial-thickness burns, ulcers (such as diabetic, pressure or venous), surgically closed incisions, and flaps and grafts. The small, mechanically powered cartridge alleviates risk of severe bleeding and exsanguination (blood loss sufficient to cause death), and the closed-system design protects patients from exposure to exudate contained within the cartridge and dressing.
In addition, the SNaP System cannot be turned off or tampered with, which ensures consistent and continual therapy to the wound. Since it is not electrically powered, there is no risk of electrocution when showering or bathing. The device is disposable, which eliminates the chance of cross-contamination, and fits easily under clothing, enabling patients to resume daily activities without revealing their wound care therapy.
“Australia and New Zealand are strategic markets for Spiracur and we are very pleased to be partnering with AinsCorp to expand our market presence in this part of the world,” said Linda LaMagna, vice president of global marketing and strategic planning for Spiracur. “We believe the device is an excellent choice for patients because it offers improved safety during their wound healing process, and does not interfere with daily activities including showering, working and socializing. Our SNaP System truly offers patients a new option that enables them to continue leading a normal lifestyle as their wounds heal, hidden from the world to see.”
Several clinical studies have been published supporting the SNaP Wound Care System as an effective alternative to electrically powered NPWT, including a comparative Randomized Controlled Trial that also showed the small device makes a positive difference in patients’ quality of life.
About AinsCorp Pty Ltd
AinsCorp is an independent Australian-owned company that is committed to providing a unique range of products to healthcare professionals. The company specializes in the supply of ostomy and wound care products to the Australian and New Zealand healthcare markets. AinsCorp is headquartered in Niddrie, a suburb of Melbourne, Victoria, Australia.
About Spiracur Inc.
Spiracur Inc., headquartered in Sunnyvale, Calif., is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford University Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System for the treatment of chronic and acute wounds, is the result of patient and clinician feedback that current negative pressure wound therapies were too cumbersome. The company’s ciSNaP® Closed Incision System with proprietary controlled tension relief is designed to improve healing of high-risk surgical incisions. Both devices have been cleared by the U.S. Food & Drug Administration (FDA) and have received CE Mark approval. Spiracur’s proprietary mechanically powered technology does no require batteries or electricity to operate. For more information, please visit http://spiracur.com.
Media Contact
Amy Cook
925.552.7893
amycook @amcpublicrelations.com
Investor Contact
Steve Van Dick
408.701.5300
svandick @spiracur.com
